Rituximab maintenance in follicular lymphoma: PRIMA (Q82989407)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21176951%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

title

Rituximab maintenance in follicular lymphoma: PRIMA (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21176951%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

1 reference

1 reference

Jonathan W Friedberg

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21176951%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

language of work or name

English

0 references

publication date

20 December 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21176951%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21176951%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

volume

377

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21176951%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

issue

9759

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21176951%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

page(s)

4-6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21176951%20AND%20SRC:MED&resulttype=core&format=json

New treatment options have changed the survival of patients with follicular lymphoma

18 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962272-6

7 January 2021

Improved survival of follicular lymphoma patients in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962272-6

7 January 2021

CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962272-6

7 January 2021

Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP al

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962272-6

7 January 2021

Unique toxicities and resistance mechanisms associated with monoclonal antibody therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962272-6

7 January 2021

Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962272-6

7 January 2021

Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962272-6

7 January 2021

Follicular lymphoma in the United States: first report of the national LymphoCare study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962272-6

7 January 2021

B cell reconstitution after rituximab treatment of lymphoma recapitulates B cell ontogeny.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962272-6

7 January 2021

Eastern Cooperative Oncology Group 4402: Rituximab Extended Schedule or Retreatment Trial (RESORT)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962272-6

7 January 2021

10.1016/S0140-6736(10)62272-6

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21176951%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

1 reference